BioSpace News Archive

Drug Development

Axovant’s Nightmare Week Continues After CEO Admits Numbers Were Even Worse Than Reported Yesterday

Vivek Ramaswamy’s Axovant has egg on its face after it was forced to own up to the fact it misreported mid-stage data on a drug it hoped to take into Phase III.

January 9, 2018
·
2 min read
·
Alex Keown
Business

Jobs Lost as Cellectar Biosciences Shutters Manufacturing Operations

Cellectar Biosciences is closing its manufacturing operations and contracting them out.

January 9, 2018
·
2 min read
·
Mark Terry
Drug Development

MabVax CEO Looks for Potential Deals at JPM to Support its Human Antibody Programs

MabVax’s antibody-based radioimmunotherapy product MVT-1075 is currently being tested on 22 patients with CA19-9 positive malignancies in a Phase I trial.

January 9, 2018
·
3 min read
·
Alex Keown
Shenzhen’s HEC Pharm Invests in U.S. Novel Imaging Contrast Company

East Sunshine Foresight Fund will make a “series of investments” of unspecified size in Enlyton, a Columbus, Ohio company developing novel imaging contrast agents.

January 9, 2018
·
1 min read
Business

Ally Bridge and LifeTech Scientific Join to Invest in MedTech Companies

The two companies will invest as partners in global medtech enterprises with the goal of accelerating their market entry and commercialization in China.

January 9, 2018
·
1 min read
Business

AbSci Appoints William F. Bennett, PhD to Scientific Advisory Board

A pioneer of the biotech industry, Dr. Bennett brings his decades of experience in downstream process development, protein purification, and regulatory affairs to the AbSci team.

January 9, 2018
·
2 min read
Business

ICON Issues Financial Guidance for Full Year 2018

For the full year 2018 revenue will be in the range of $1,870 - $1,930 million, representing growth of 7 - 10% and earnings per share will be in the range of $5.89 - $6.09, representing growth of 10 - 13%.

January 9, 2018
·
4 min read
Business

ICON Appoints Dr. James Cummings as President of ClinicalRM

Dr. Cummings has over 20 years’ experience within the global health and government research and development industries.

January 9, 2018
·
4 min read
Biotech Beach

SoCal’s Evolus Files for $75M IPO

Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers for the offering.

January 9, 2018
·
2 min read
Pharm Country

Teleflex Surpasses 200,000 Successfully Reprocessed ClosureFast® Catheters

Teleflex announced that more than 200,000 ClosureFast® Catheters have been successfully reprocessed by the company’s partner, Northeast Scientific, Inc. (NES), since NES received FDA clearance for reprocessing the popular vein ablation catheter in 2011.

January 9, 2018
·
5 min read